

• **Name:**

Hong Jae Chon, MD, PhD

• **Current Position:**

Associate Professor, Medical Oncology, Department of Internal Medicine,

CHA Bundang Medical Center, CHA University,

• **Country:**

South Korea

• **Educational Background:**

1998.3.-2005.2. **MD, Yonsei University College of Medicine, Seoul, Korea.**

2008.3.-2018.8. **PhD, Yonsei Graduate School, Seoul, College of Medicine, Korea,**

• **Professional Experience:**

2005.3.-2006.2. **Rotating internship, Severance Hospital,**

Yonsei University College of Medicine, Seoul, Korea

2006.3.-2010.2. **Residency in Internal Medicine, Severance Hospital,**

Yonsei University College of Medicine, Seoul, Korea

2013.5.-2014.2 **Clinical Fellow, Division of Medical Oncology, Severance Hospital,**

Yonsei University College of Medicine, Seoul, Korea

2014.3.-2015.8 **Clinical Research Professor, Division of Medical Oncology, Severance Hospital, Yonsei**

University College of Medicine, Seoul, Korea

2015.9.- **Assistant Professor, Medical Oncology,**

CHA Bundang Medical Center, CHA University, Seongnam, Korea

2019.3.- Associate Professor, Medical Oncology,

CHA Bundang Medical Center, CHA University, Seongnam, Korea

• **Professional Organizations:**

Active member of ASCO (American Society of Clinical Oncology)

Active member of AACR (American Association for Cancer Research)

Active member of KSMO (Korean Society of Medical Oncology)

Active member of KCA (Korean Cancer Association)

Active member of KCSG (Korean Cancer Study Group)

• **Main Scientific Publications:**

1. Kim C*, **Chon HJ***, Kim JH, Jung M, Nam JM, Kim HS, Kang B, Chung HC, Rha SY. Randomized phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer. *European Journal of Cancer* **2018** (IF 7.191) (***Co-first author**)
2. **Chon HJ***, Lee WS*, Yang H, Kong SJ, Lee NK, Moon ES, Choi J, Han EC, Kim JH, Ahn JB, Kim JH, Kim C. Tumor microenvironment remodeling by intratumoral oncolytic vaccinia virus enhances the efficacy of immune checkpoint blockade. *Clinical Cancer Research* **2019** (IF 10.199)
3. **Chon HJ***, Kim C*, Cho A, Kim YM, Jang SJ, Kim BO, Park CH, Hyung WJ, Ahn JB, Noh SH, Yun M, Rha SY. The Clinical Implications of FDG-PET/CT Differ According to Histology in Advanced Gastric Cancer. *Gastric Cancer* **2018** (IF 5.454) (***E-pub***)
4. Kim C, Kim WR, Kim KY, **Chon H**, Beom SH, Kim H, Jung M, Shin SJ, Kim N, Ahn JB. Predictive Nomogram for Recurrence of Stage I Colorectal Cancer Following Curative Resection. *Clinical Colorectal Cancer* **2018** (IF 4.507);17(3):e513-e518.
5. Kim HS, **Chon HJ**, Kim HK, Shin SJ, Wacheck Volker, Gruver AM, Kim JS, Rha SY, Chung HC. MET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver metastasis. *Journal of SURGICAL ONCOLOGY* **2018** (IF 2.886)
6. Kim C*, Lee C*, **Chon HJ***, Kim JH, Park HS, Heo SJ, Kim HJ, Kim TS, Kwon WS, Chung HC, Rha SY. PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer. *Oncotarget* **2017** (IF 5.168), **8(69):113494-501** (***Co-first author**)
7. Park HS, Park JS, Chun YJ, Roh YH, Moon J, **Chon HJ**, Choi HJ, Park JS, Lee DK, Lee SJ, Yoon, DS, Jeung HC. Prognostic factors and scoring model for survival in metastatic biliary tract cancer. *Cancer Res Treat* **2017** (IF 3.230)
8. **Chon HJ***, Hyung WJ*, Kim, C, Park SH, Kim JH, Park CH, Ahn JB, Kim HK, Chung HC, Rha SY, Noh SH, Jeung HC. Different implication of gastric signet ring cell carcinoma. *Annals of Surgery* **2017** (IF 9.203)
9. Kim C, Yoo KH, Kim MH, **Chon HJ**, Lee SI, Koh S, Lee HY, Lee HR, Kim KS, Choi YD, Rha SY, Lee SJ, Kim HS. Different Subtypes of Epithelioid Sarcoma and Their Clinical Implication: Long-term Multi-Institutional Experience with a Rare Sarcoma. *APMIS* **2017** (IF 1.933), 125:223-229
10. Kim C, Kim EK, Jung H, **Chon HJ**, Han JW, Shin KH, Hu H, Kim KS, Choi YD, Kim S, Lee YH, Suh JS, Ahn JB, Chung HC, Noh SH, Rha SY, Kim SH, Kim HS. Prognostic Implications of PD-L1 Expression in Patients with Soft Tissue Sarcoma. *BMC Cancer* **2016** (IF 3.265), 16:434